Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
261. |
ECCT/20/06/05 | SEVUSMART Trial SEVUSMART TRIAL Sevuparin as a potential adjunctive therapy in children with severe malaria |
Principal Investigator(s) 1. Kathryn Maitland Maitland Site(s) in Kenya Kilifi County Hospital |
View |
262. |
ECCT/20/06/04 | ANTICOV (01 COV) An open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild /moderate cases of COVID-19 |
Principal Investigator(s) 1. Bernhards Ragama Ogutu Site(s) in Kenya 1. Mbagathi Infectious Disease Hospital (Nairobi City county) 2. Kenyatta University Teaching, Referral and Research Hospital (Nairobi City county) |
View |
263. |
ECCT/20/06/03 | CVIA078 A Phase 2b randomized, open-label, controlled, single center study in Plasmodium falciparum-infected and uninfected adults age 18-55 years old in Kenya to evaluate the efficacy of the delayed, fractional dose RTS,S/AS01E malaria vaccine in subjects treated with artemisinin combination therapy plus primaquine |
Principal Investigator(s) 1. Nathanial Kelsey Copeland Site(s) in Kenya Kombewa Clinical Research Centre |
View |
264. |
ECCT/20/06/02 | EMPACTA Covid19 Study A RANDOMIZED, DOUBLE-BLIND, Placebo-Controlled, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TOCILIZUMAB IN HOSPITALIZED PATIENTS WITH COVID‑19 PNEUMONIA |
Principal Investigator(s) 1. Reena Shah Site(s) in Kenya AgaKhan University Hospital Nairobi |
View |
265. |
ECCT/20/06/01 | IAVI C100 Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults |
Principal Investigator(s) 1. Prof Walter Jaoko Godfrey Jaoko Site(s) in Kenya 1. KAVI-Insitute of Clinical Research, KNH site (Nairobi City county) |
View |